Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
Lead Sponsor:
Akeso
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.
Detailed Description
This is a Phase 3 clinical study to evaluate the efficacy and safety of AK102 Q6W, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), in subjects with primary hyperch...
Eligibility Criteria
Inclusion
- Subject understand and voluntarily sign the written Inform Consent Form (ICF).
- Male or female ≥ 18 to ≤ 80 years of age.
- The fasting serum LDL-C level of subjects did not meet the treatment goal after at least 4 weeks of stable lipid-lowering background treatment.
- TG ≤ 4.5 mmol/L (400 mg/dl)
Exclusion
- Known homozygous familial hypercholesterolemia.
- Received PCSK9 inhibitors within 6 months before randomization.
- Known sensitivity to PCSK9 inhibitors and any substances to be administered.
- Severe renal dysfunction.
- Previously received organ transplantation.
- Uncontrolled hypothyroidism or hyperthyroidism.
- Uncontrolled hypertension.
- Known hyperlipidemia secondary to comorbidity, including nephrotic syndrome, cholestatic liver failure, etc.
- History of malignancy of any organ system within the past 5 years.
Key Trial Info
Start Date :
January 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2022
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT05260411
Start Date
January 26 2022
End Date
December 19 2022
Last Update
March 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
2
Zhongshan Hospital, Fudan Hospital
Shanghai, China